- Home
- SAVA vs GALT Comparison
SAVA vs GALT Comparison
Compare SAVA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- GALT
- Stock Information
- Founded
- SAVA 1998
- GALT 2000
- Country
- SAVA United States
- GALT United States
- Employees
- SAVA N/A
- GALT N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- GALT Health Care
- Exchange
- SAVA Nasdaq
- GALT Nasdaq
- Market Cap
- SAVA 70.5M
- GALT 83.5M
- IPO Year
- SAVA N/A
- GALT N/A
- Fundamental
- Price
- SAVA $2.05
- GALT $1.37
- Analyst Decision
- SAVA Buy
- GALT Hold
- Analyst Count
- SAVA 3
- GALT 1
- Target Price
- SAVA $54.50
- GALT N/A
- AVG Volume (30 Days)
- SAVA 1.2M
- GALT 166.6K
- Earning Date
- SAVA 08-07-2025
- GALT 08-12-2025
- Dividend Yield
- SAVA N/A
- GALT N/A
- EPS Growth
- SAVA N/A
- GALT N/A
- EPS
- SAVA N/A
- GALT N/A
- Revenue
- SAVA N/A
- GALT N/A
- Revenue This Year
- SAVA N/A
- GALT N/A
- Revenue Next Year
- SAVA N/A
- GALT N/A
- P/E Ratio
- SAVA N/A
- GALT N/A
- Revenue Growth
- SAVA N/A
- GALT N/A
- 52 Week Low
- SAVA $1.15
- GALT $0.73
- 52 Week High
- SAVA $42.20
- GALT $3.17
- Technical
- Relative Strength Index (RSI)
- SAVA 51.70
- GALT 55.58
- Support Level
- SAVA $2.02
- GALT $1.28
- Resistance Level
- SAVA $2.25
- GALT $1.36
- Average True Range (ATR)
- SAVA 0.11
- GALT 0.07
- MACD
- SAVA -0.02
- GALT 0.01
- Stochastic Oscillator
- SAVA 29.03
- GALT 88.24
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.